Navigation Links
Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
Date:10/16/2007

- Data to be presented November 2 at the American Society of Nephrology

Meeting -

SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced that a recently completed phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy. Exelixis is continuing to analyze the data to assess whether further evaluation of the compound is warranted.

Proteinuria, the presence of excess protein in the urine, is an indicator of renal disease. Albumin excretion is a risk factor for kidney failure, stroke and cardiovascular and all-cause mortality, particularly in patients with diabetes and/or hypertension. Nephropathy (kidney disease) is a common problem in diabetic patients, often leading to the need for hemodialysis or kidney transplant. XL784 is a potent small molecule inhibitor of MMP2 and ADAM10, metalloprotease enzymes that may play a role in renal fibrosis and impairment.

"We obviously are disappointed that this trial did not meet its primary endpoint," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "However, the compound was well tolerated, and we are continuing to analyze the data to determine if the compound may have utility in the treatment of diabetic nephropathy. We will provide an update on our plans for XL784 once we complete our analysis of the data."

The complete safety and efficacy data from the phase 2 trial of XL784 in diabetic patients with proteinuria are scheduled for presentation on November 2, 2007, at the American Society of Nephrology (ASN) Renal Week 2007, which is b
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 Pepperl+Fuchs, a world ... MACTek Corporation, a leading provider of HART protocol ... to further extend its integrated solutions offerings and ... "We are pleased to add the ... said Jim Bolin , Pepperl+Fuchs, executive vice ...
(Date:8/31/2015)... 2015 Thousands of people will peacefully demonstrate ... opioid addiction epidemic at dozens of rallies across the ... the United States has experienced ... opioids and heroin, yet the President has never once ... letter to President Obama , rally organizers compared ...
(Date:8/31/2015)... , August 31, 2015 ... that the global cardiovascular monitoring and diagnostic devices ... is predicted to reach a value of approximately ... of 9.7% between 2013 and 2019. The title ... Devices Market (ECG, Holter Monitors, Event Monitors, Cardiovascular ...
Breaking Medicine Technology:Obama Administration's Neglect of Opioid Crisis Prompts Rallies in Many States 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 2Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 3Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 4Cardiovascular Monitoring and Diagnostic Devices Market to Reach US$7.0 Billion in 2019 Owing to Global Rise in Diabetes and Obesity: Transparency Market Research 5
... JERUSALEM , June 2, ... oral drug delivery systems, announced,today that its subsidiary Oramed Ltd. ... ("Laser Detect"), an Israeli company listed on,the Tel Aviv Stock ... Entera Bio Ltd. ("Entera"). Under the terms of the agreement, ...
... Questcor Pharmaceuticals, Inc . (Nasdaq: QCOR ) announced today that it ... June 10, 2010 at The Grand Hyatt Hotel in New York, ... will discuss the Company,s business strategy and historical financial performance at 11:30 ... , Attendance at ...
Cached Medicine Technology:Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 2Oramed Pharmaceuticals Forms Joint Venture - Launches Entera Bio Ltd. 3Questcor to Present at the Jefferies 2010 Global Life Sciences Conference 2
(Date:9/1/2015)... Greifensee, Switzerland (PRWEB) , ... September 01, 2015 ... ... “Calibration and Qualification of Laboratory Instruments in accordance with GMP requirements“ , ... be presented on October 6th, 2015 at 11:00 EDT (15:00 GMT). , ...
(Date:9/1/2015)... , ... September 01, 2015 , ... Mercy Health (formerly ... devoted the 10th of its monthly Mercy Health: Helping You Be Well videos to ... in seven men. , In a concise video on Mercy Health’s YouTube channel, ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... 9, 2015 from 5:00 to 8:00 pm at the Marriott Indianapolis Downtown, 350 ... with career opportunities will be attending from across the country. All specialties will ...
(Date:9/1/2015)... ... September 01, 2015 , ... Éminence Organic Skin Care ... VitaSkin™ Exfoliating Peels. This revolutionary collection of natural peel solutions complements the existing ... , Formulated with alpha hydroxy acids and natural active ingredients, these results-oriented ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... has established the MAP Recovery Network, the Premier Outcomes-Driven Provider Network. It ... rapidly-growing alliance is dedicated to the provision of quality addiction treatment and ...
Breaking Medicine News(10 mins):Health News:Live Webinar from Pharmaceutical Technology and METTLER TOLEDO on Calibration and Qualification of Laboratory Instruments 2Health News:New Mercy Health Video Explains Most-Common Cancer Found in Men 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 3Health News:PracticeMatch to Host Physician Career Fair at the Marriott Indianapolis Downtown on September 9, 2015 4Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 2Health News:Éminence Organic Skin Care Introduces Results-Oriented Exfoliating Peels for Every Skin Type 3Health News:MAP Health Management Launches the MAP Recovery Network 2
... Ill., and Rockville, Md., SAN JOSE, Calif., ... major fundraising events for the Coalition for Pulmonary,Fibrosis ... benefiting the,CPF collectively raised more than a half ... families fighting pulmonary fibrosis (PF) and,directly funds research. ...
... of Undergraduate and Graduate Programs, Now Offered at ... Board of Trustees, in,conjunction with President James J. Gozzo, ... its name to become Albany College,of Pharmacy and Health ... Board of Education, has been chosen to better reflect ...
... efficiently, study says , , THURSDAY, Oct. 16 (HealthDay News) ... the body, while being physically fit decreases it, according to ... 452 healthy men who had levels of different groups of ... cell count is a marker of inflammatory activity and is ...
... divorce, or even the loss of jobs or financial security, the mental ... inaccurate Stages Theory of Grief. At long last, Grief Recovery pioneers, Russell ... grief really is what it definitely isn,t. , ... Sherman Oaks, CA ...
... China, Oct. 16 /Xinhua-PRNewswire/ -- WuXi PharmaTech,(Cayman) ... pharmaceutical, biotechnology and,medical device research and development ... United States, today announced it has reached ... & Development, Division of,Janssen Pharmaceutica, N.V. (J&JPRD) ...
... 15 Young Innovations, Inc.,(Nasdaq: YDNT ) today ... with a live and on-demand web cast conference call ... live audio broadcast of the,call will be available through ... broadcast will also be available through the,Company,s website, ...
Cached Medicine News:Health News:CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 2Health News:CPF Fundraisers Bring in Landmark Half Million Dollars in Less Than Three Weeks 3Health News:Albany College of Pharmacy and Health Sciences - New Name, Same Commitment to the Advancement of Health Care 2Health News:Fatness Boosts Inflammation in Body 2Health News:Stages Of Grief Refuted As Inaccurate and Dangerous By Grief Recovery Institute Founders In Skeptic Magazine Article 2Health News:Stages Of Grief Refuted As Inaccurate and Dangerous By Grief Recovery Institute Founders In Skeptic Magazine Article 3Health News:Stages Of Grief Refuted As Inaccurate and Dangerous By Grief Recovery Institute Founders In Skeptic Magazine Article 4Health News:WuXi PharmaTech Expands Collaboration for Fully Integrated Services 2Health News:Young Innovations, Inc. Provides Third Quarter Conference Call Details 2
... Chamber Lenses: The Bausch & Lomb PMMA Posterior ... for primary implantation for the visual correction of ... older where a cataractous lens has been removed ... to be placed in the ciliary sulcus or ...
... are manufactured using the highest ... CQ UV PMMA material is ... single piece lenses. Unioptic lens ... nonphaco and phaco styles. All ...
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
... viscoelastic agent for the surgeon who performs ... Amvisc possesses sufficient viscosity for excellent chamber ... cohesive so that complete removal at the ... quickly accomplished. Amvisc is priced to compete ...
Medicine Products: